Simultaneously, we also observed that PKM2 overexpression in glioma cells resisted the effects of trametinib treatment in vivo, while glioma cells co-transfected with PKM2 overexpression and c-myc knockout could restore the initial therapeutic effects of trametinib treatment hindered by PKM2 overexpression. Here, MYC is linked to glioma.